Protocol Ledger

NCT05964413 · Phase III · TERMINATED

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Interventional Phase III clinical trial protocol NCT05964413 sponsored by InflaRx in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-01 Enrollment: 54 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05964413
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)54 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05964413
Protocol FieldVerified Registry Value
NCT IdentifierNCT05964413
Consolidated Lead SponsorInflaRx
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment54 participants (ACTUAL)
Registered Start Date2023-11-01
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI